-
The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer
-
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
-
Chemo‐Immunotherapy, a Combination Approach for the Treatment of HER2‐Positive Breast Cancer in a Mouse Model
-
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
-
A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection
-
HER2 Expression and Axillary Metastasis in Treatment-Naïve Early Breast Cancer
-
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France
-
Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence
-
HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies
-
Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer
-
Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices
-
Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer
-
Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam
-
HER2 Overexpression in Invasive Breast Carcinoma in the Democratic Republic of Congo and its Association with Selected Clinicopathological Characteristics
-
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
-
Research Progress of HER2 in Cervical Carcinoma
-
Regulation, Function, and Expression of Matrix Metalloproteinase-9 in Colon, Lung, and Breast Cancers In Silico and Experimental Methods From Iraqi Metastatic Patients
-
Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal Cancer
-
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
-
Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study
-
Microenvironmental Cues That Regulate Cancer Cell Dormancy in Estrogen‐Receptor Positive and Triple‐Negative Breast Cancer Cell Lines
-
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy
-
Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer
-
AIM2 Lactylation Regulates Radiotherapy Sensitivity in Triple-Negative Breast Cancer
